NantKwest

NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virus-induced infectious diseases. NantKwest is a leading producer of off-the-shelf natural killer (NK) cell therapies in clinical dosage form. The activated NK cell platform is designed to destroy cancer cells and virus-infected cells. The safety of these optimized activated NK cells — as well as their activity against various cancers — has been evaluated in Phase I clinical trials in Canada and Europe, and in multiple Phase I and II clinical trials in the United States.